Sarepta Therapeutics, Inc. — Form 8-K
Filed July 27, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 62/100
What the filing says
Michael Severino, M.D., appointed CEO of Sarepta effective July 28, 2026, replacing retiring Doug Ingram. Severino receives $1.18M annual base salary, 110% target bonus ($1.298M), and a $35M sign-on equity grant (mix of RSUs and premium-priced options vesting over 4 years). Ingram transitions to consultant at $15K/month through December 31, 2026. Severino, former AbbVie VP and Tessera CEO, brings 25+ years pharma experience; joins board immediately.
Why this rating
Leadership transition material for strategy/execution; $35M equity (~2% of $1.7B market cap) and $1.18M salary meaningful but not transformative. Severino's pharma pedigree positive; execution risk on pipeline remains.
See more from July 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.